2020
Psychiatric comorbidity and social adjustment difficulties in children with disruptive mood dysregulation disorder: A national epidemiological study
Lin YJ, Tseng WL, Gau SS. Psychiatric comorbidity and social adjustment difficulties in children with disruptive mood dysregulation disorder: A national epidemiological study. Journal Of Affective Disorders 2020, 281: 485-492. PMID: 33383391, PMCID: PMC8142276, DOI: 10.1016/j.jad.2020.12.039.Peer-Reviewed Original ResearchConceptsDisruptive mood dysregulation disorderOppositional defiant disorderSocial adjustment difficultiesAdjustment difficultiesPsychiatric comorbiditySocial Adjustment InventoryKiddie epidemiologic versionParent-child interactionsChildhood mental disordersAdjustment InventoryDefiant disorderEpidemiologic VersionParental educational levelAcademic performanceMore difficultyDSM-5More problemsHigh psychiatric comorbiditySchool functionTaiwanese childrenMental disordersNational epidemiological studyChildrenAffective disordersSevere impairment
2007
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, Tseng WL, Allen AJ, Lee P. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2007, 17: 447-460. PMID: 17822340, DOI: 10.1089/cap.2006.0091.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic Uptake InhibitorsAppetiteAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityChildDouble-Blind MethodDrug Administration ScheduleFacultyFemaleHumansMaleNauseaParentsPropylaminesPsychiatric Status Rating ScalesSeverity of Illness IndexTaiwanTreatment OutcomeConceptsAttention-deficit/hyperactivity disorderPrimary efficacy measureEfficacy measuresDaily atomoxetineAdverse eventsADHD Rating Scale-IV-Parent VersionDrug-related serious adverse eventsHyperactivity disorderSecondary efficacy measuresSerious adverse eventsClinical Global ImpressionCarried-forward approachEnd of studyTreatment effect sizeAtomoxetine groupPlacebo groupTreat basisPediatric patientsGlobal ImpressionSafe treatmentClinical trialsInvestigator AdministeredEdition criteriaTreatment groupsMental disorders